(12M)-(1S,2S)-N-((63S,4S,Z)-11-Ethyl-12-(2-((S)-1-Methoxyethyl)-5-(4-Methylpiperazin-1-Yl)Pyridin-3-Yl)-10,10-Dimethyl-5,7-Dioxo-61,62,63,64,65,66-Hexahydro-11H-8-Oxa-2(4,2)-Thiazola-1(5,3)-Indola-6(1,3)-Pyridazinacycloundecaphane-4-Yl)-2-Methylcyclopropane-1-Carboxamide

6 trials 4 recruiting

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

4 Recruiting

1 Completed trials

1 Sponsors

12 Countries

Phase III

Phase II

Phase I (Other)

Phase III: 3 Phase II: 1 Phase I (Other): 2

Oversight events:

3 temporary halts across 1 trial

View oversight register →

Indications tested

Non-small cell lung cancer 4 Ductal adenocarcinoma of pancreas 1

Sponsors using this IMP

Revolution Medicines Inc. 6

All trials

6 total

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 304) Pending

2025-523495-23-00 Phase III 4 countries Revolution Medicines Inc.
Study of zoldonrasib with or without daraxonrasib and other anticancer drugs in patients with RAS G12D-mutant non-small cell lung cancer (NS… Recruiting

2025-521147-21-00 Phase II 9 countries Revolution Medicines Inc.
Study of Daraxonrasib (RMC-6236) in Patients with RAS Mutated NSCLC Recruiting

2024-518154-16-00 Phase III 8 countries Revolution Medicines Inc.
Study of RMC-6291 and RMC-6236 With Other Anti-Cancer Agents in Patients With RAS G12C-Mutated NSCLC - Subprotocol A Recruiting

2023-509571-16-00 Phase I (Other) 5 countries Revolution Medicines Inc.
A study of RMC-6236 in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B Recruiting

2023-509572-42-00 Phase I (Other) 5 countries Revolution Medicines Inc.
Phase 3 study of RMC-6236 in patients with previously treated metastatic PDAC Ended

2024-516063-89-00 Phase III 4 countries Revolution Medicines Inc.

Showing 1–6 of 6 trials

← All drugs A–Z